Evaluation of the effect of intranasal infiltrated botulinum toxin-A on a model of allergic rhinitis in rabbits: An Experimental Study

Güneş, Murat Salih; Külahlı, İsmail; Kökoğlu, Kerem; Vural, Alperen; Avcı, Deniz; Güleç, Şafak; Sönmez, Mehmet Fatih; Çilenk, Kübra Tuğba; Erçal, Barış Derya

doi:10.1016/j.ijporl.2016.01.010

Cited by 6 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the rabbit model of AR defined by Güneş et al (7) 30 mg of OVA in 100 mL of saline was administered intraperitoneally to rabbits every other day for 14 days. Then AR was induced in rabbits by intranasal application of OVA twice a day between the 14 th and 18 th days.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A New Experimental Allergic Rhinitis Model in Mice

Köse¹,

Kiş²,

Diniz³

et al. 2021

BUCH

View full text Add to dashboard Cite

Objective: Allergic rhinitis (AR) is an inflammatory disease of the nasal mucosa mediated by IgE after exposure to an allergen. The most well known related comorbidity of AR is asthma. This study was planned due to the need for an animal model for studies on AR-asthma coexistence. In this study, the frequency of AR accompanying in the asthma model created in mice,and the usability of the related model in AR studies will be investigated. Methods: In our study, 6-8 week-old, 18-20 g BALB/c mice were used. Chicken egg ovalbumin (OVA Grade V, Sigma) was administered through intraperitoneal (IP) route at doses of 10 μg on days 0 and 14. Mice were exposed to aerosolized 2.5% ovalbumin solution in sterile saline for 30 minutes 3 days a week for 8 weeks, starting 7 days after the last IP administration (21st day). After exposure to OVA, mice were observed for typical signs of AR including sneezing, runny nose, and nasal itching. The final diagnosis of AR was made by histopathological examination of the rhinotracheal tissues of mice. Results: In our study, all mice exposed to ovalbumin received histopathologic diagnosis of AR. Increased number of capillaries lymphocytes, polymorphonuclear leukocytes and eosinophilsper square millimetre of rhinotracheal tissues were calculated in the murine model of AR compared to the the control group. Conclusion: This study introduced a new AR model, not cited in the literature, and induced with the longest-term ovalbumin exposure in the literature. It was concluded that this model, known as the asthma model, can also be used to induce an AR model and can be used in studies investigating coexistence of allergic rhinitis and asthma.

show abstract

Section: Discussionmentioning

confidence: 99%

“…Animal models of AR are extremely important for research studies on AR. To date, guinea pigs, mice, rats and rabbits have been used in animal models of AR (4)(5)(6)(7)(8) . Firstly, guinea pigs were used, and BALB/c type mice have been used mostly in recent years (4) .…”

mentioning

confidence: 99%

A New Experimental Allergic Rhinitis Model in Mice

Köse¹,

Kiş²,

Diniz³

et al. 2021

BUCH

View full text Add to dashboard Cite

show abstract

“…Multiple previous animal studies were conducted to determine the clinical and histological effect of BTX on nasal mucosa, Aoishi et al [36] using single intranasal BTX infusion in mice model of AR reported significantly decreased nasal serous discharge and sneezing with decreased capillary dilatation and eosinophil infiltration by Day 3 after infusion without change in number and size of nasal mucosal secretary glands and Güneş et al [37] found BTX infiltration in the inferior turbinates of rabbit model of resulted in decreased nasal discharge, scratching and blockage and reorganization of histopathological findings of AR with significant difference between disease and treatment groups.…”

Section: Disucssionmentioning

confidence: 99%

Comparative study between Intranasal Injection of Botulinum Toxin-A and Combined Intranasal Medical Treatment for Allergic Rhinitis

Sarhan

Fathallah

Wahba

et al. 2020

International Journal of Medical Arts

View full text Add to dashboard Cite

Background: Allergic rhinitis is one of the most common diseases, with no consensus on its ideal treatment. Botulinum Toxin-A was proposed to be an effective treatment. Aim of the work: To estimate the outcome of intranasal injection of Botulinum Toxin-A [BTX-A] as a sole therapy for allergic rhinitis. Patients and Methods: Ninty patients with classic symptoms of allergic rhinitis were clinically evaluated and asked to complete the score for allergic rhinitis [SFAR] questionnaire using cutoff at >8 as diagnostic AR. Two blood samples [venous] and nasal smears were obtained at the beginning of the study and at the end of 12-weeks after initiation of therapy for estimation of human immunoglobulin E [IgE] and eosinophilia grading. Control group included patients who chose to receive combined medical treatment. BTX-A, 2.5 units were injected intranasally, under 0o rigid telescope guidance. Study outcome was the treatment success rate at the end of 12-w follow-up period. Results: Intranasal BTX-A injection provided significantly maintained relieve of allergic rhinitis manifestations especially for running nose than combination therapy. The treatment success rate of 1.9 versus 0.7 item/patient in study versus control group with significant difference in favor of BTX-A injection. Serum IgE levels and eosinophilia grades were significantly lower in control patients. Patients' satisfaction grading was significantly more with BTX-A injection. Conclusion: Intranasal BTX injection could be a safe and effective sole therapeutic modality for patients with long-lasting AR.

show abstract

Botulinum Toxin for Rhinitis

Özcan

İsmi

2016

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Botulinum toxin is an exotoxin generated by Clostridium botulinum. It disturbs the signal transmission at the neuromuscular and neuroglandular junction by inhibiting the acetylcholine release from the presynaptic nerve terminal. It has been widely used in neuromuscular, hypersecretory, and autonomic nerve system disorders. There have been a lot of published articles concerning the effect of this toxin on rhinitis symptoms. Based on the results of these reports, intranasal botulinum toxin A administration appears to be a safe and effective treatment method for decreasing rhinitis symptoms in rhinitis patients with a long-lasting effect. Botulinum toxin type A will be a good treatment option for the chronic rhinitis patients who are resistant to other treatment methods.

show abstract

Evaluation of the effect of intranasal infiltrated botulinum toxin-A on a model of allergic rhinitis in rabbits: An Experimental Study

Cited by 6 publications

References 26 publications

A New Experimental Allergic Rhinitis Model in Mice

A New Experimental Allergic Rhinitis Model in Mice

Comparative study between Intranasal Injection of Botulinum Toxin-A and Combined Intranasal Medical Treatment for Allergic Rhinitis

Botulinum Toxin for Rhinitis

Contact Info

Product

Resources

About